Síntese de adutos de Morita-Baylis-Hillman simétricos derivados de isatina com atividade anticâncer e leishmanicida

Detalhes bibliográficos
Autor(a) principal: Coelho, Maísa Cavalcanti
Data de Publicação: 2023
Tipo de documento: Tese
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações da UFPB
Texto Completo: https://repositorio.ufpb.br/jspui/handle/123456789/30921
Resumo: Two important questions in human health, cancer and leishmaniasis have usual treatments that include injectable medicine with a lot of adverse effects, high cost and sometimes ineffective. In the context of need of new drugs development, the 3-hydroxy-2-oxindol scaffold is present in synthetic molecules with antiproliferative and leishmanicidal properties. In order to synthetize this nucleus, the Morita-Baylis-Hillman reaction (MBHR) can be used, and some adducts are already reported as anti-leishmania and antitumor. With the purpose of enhancing this activity, we used a molecular dimerization approach in the design of the novel molecules. The aim of this work was to obtain new dimmeric Morita-Baylis-Hillman adducts with potential antiproliferative and antiparasitic activity, containing the 3-hydroxy-2-oxindol nucleus formed by Morita-Baylis-Hillman reaction, using isatin as substrate. The synthetic route involved the synthesis of 10 isatin derivatives, the ethyleneglycol acrylate and the MBHR synthesis, forming the dimmeric Morita-Baylis-Hillman Adducts (MBHA). Variables as solvent, temperature, different catalysts and increasing proportions of DABCO (25 to 100%) were tested in the MBHA synthetic optimization. The novel dimmers were characterized by mass spectrometry, Fourier transform infrared (FTIR), 1H and 13C Nuclear Magnetic Resonance (NMR). Room temperature, DABCO 100 mol% and DMF were chosen as the best reaction conditions, with 43% yield in the case of the dimer used in the optimization study (1a, N-metilado). The reaction time varyied between 15 minutes to 11 days, and yields between 24 and 67%. 10 original dimmers were biologically evaluated in the cancer cell lines K-569, HL-60 e A-549 and also in promastigotes and amastigotes of Leishmania infantum. Among the adducts sent to antiproliferative evaluation, 1h, a Nbenzilated and dichlorated dimmer, presented strong activity against all the strains (IC50 0,72 to 2,24 μM and SI 0,6 to 1,87), as well 1f, a N-metilated and dichlorated dimmer (IC50 1,18 to 3,83 μM and SI 1,8 a 5,84), being both considered promising. The dimmers of this work (IC50 1,18 to 7,94 μM) were more active than the existing correspondent monomers (IC50 4,2 to 16,08 μM) reported in the literature, evidencing the efficacy of dimmerization approach in this case. The in vitro tests in Leishmania infantum showed 1h and 1f as the most active too, with IC50 of 5,48 and 5,7 μM, respectively, in the amastigote form of the parasite.
id UFPB_ea96d2d41bd20fe290ed245fa024785d
oai_identifier_str oai:repositorio.ufpb.br:123456789/30921
network_acronym_str UFPB
network_name_str Biblioteca Digital de Teses e Dissertações da UFPB
repository_id_str
spelling Síntese de adutos de Morita-Baylis-Hillman simétricos derivados de isatina com atividade anticâncer e leishmanicidaQuímicaAdutos de Morita-Baylis-HillmanAtividade antiproliferativaAtividade antiparasitáriaAceptor de MichaelSimetria molecularMorita-Baylis-Hillman adductsMichael acceptorMolecular symmetryAntiproliferative activityAntiparasitic activity3-hidroxy-2-oxindolCNPQ::CIENCIAS EXATAS E DA TERRA::QUIMICATwo important questions in human health, cancer and leishmaniasis have usual treatments that include injectable medicine with a lot of adverse effects, high cost and sometimes ineffective. In the context of need of new drugs development, the 3-hydroxy-2-oxindol scaffold is present in synthetic molecules with antiproliferative and leishmanicidal properties. In order to synthetize this nucleus, the Morita-Baylis-Hillman reaction (MBHR) can be used, and some adducts are already reported as anti-leishmania and antitumor. With the purpose of enhancing this activity, we used a molecular dimerization approach in the design of the novel molecules. The aim of this work was to obtain new dimmeric Morita-Baylis-Hillman adducts with potential antiproliferative and antiparasitic activity, containing the 3-hydroxy-2-oxindol nucleus formed by Morita-Baylis-Hillman reaction, using isatin as substrate. The synthetic route involved the synthesis of 10 isatin derivatives, the ethyleneglycol acrylate and the MBHR synthesis, forming the dimmeric Morita-Baylis-Hillman Adducts (MBHA). Variables as solvent, temperature, different catalysts and increasing proportions of DABCO (25 to 100%) were tested in the MBHA synthetic optimization. The novel dimmers were characterized by mass spectrometry, Fourier transform infrared (FTIR), 1H and 13C Nuclear Magnetic Resonance (NMR). Room temperature, DABCO 100 mol% and DMF were chosen as the best reaction conditions, with 43% yield in the case of the dimer used in the optimization study (1a, N-metilado). The reaction time varyied between 15 minutes to 11 days, and yields between 24 and 67%. 10 original dimmers were biologically evaluated in the cancer cell lines K-569, HL-60 e A-549 and also in promastigotes and amastigotes of Leishmania infantum. Among the adducts sent to antiproliferative evaluation, 1h, a Nbenzilated and dichlorated dimmer, presented strong activity against all the strains (IC50 0,72 to 2,24 μM and SI 0,6 to 1,87), as well 1f, a N-metilated and dichlorated dimmer (IC50 1,18 to 3,83 μM and SI 1,8 a 5,84), being both considered promising. The dimmers of this work (IC50 1,18 to 7,94 μM) were more active than the existing correspondent monomers (IC50 4,2 to 16,08 μM) reported in the literature, evidencing the efficacy of dimmerization approach in this case. The in vitro tests in Leishmania infantum showed 1h and 1f as the most active too, with IC50 of 5,48 and 5,7 μM, respectively, in the amastigote form of the parasite.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESDuas questões importantes na saúde humana, o câncer e a leishmaniose têm tratamentos usuais que incluem medicamentos injetáveis com muitos efeitos adversos, caros e por vezes ineficazes. No contexto necessário de desenvolvimento de novos fármacos, o núcleo 3- hidróxi-2-oxindol está presente em moléculas sintéticas com propriedades antiproliferativa e leishmanicida. Para sintetizar este núcleo, a reação de Morita-Baylis-Hillman (RMBH) pode ser utilizada, sendo alguns adutos também já relatados como anti-leishmania e antitumorais. A fim de potencializar esta atividade, utilizamos a abordagem de dimerização molecular no desenho das moléculas inéditas. O objetivo do trabalho foi obter novos adutos diméricos com potencial atividades antiproliferativa e antiparasitária, contendo o núcleo 3-hidróxi-2-oxindol formado a partir da reação de Morita-Baylis-Hillman usando a isatina como substrato. A rota sintética envolveu a síntese de 10 derivados de isatinas, o diacrilato de etilenoglicol e a RMBH formando os adutos de Morita-Baylis-Hillman (AMBH) diméricos. Variáveis como solvente, temperatura, catalisadores diferentes e proporções crescentes de DABCO (25 a 100%) foram testadas na otimização sintética dos AMBH. Os dímeros inéditos foram caracterizados por espectrometria de massas, espectroscopia de infravermelho, ressonância magnética nuclear (RMN) de 1H e de 13C. O uso de temperatura ambiente, DABCO 100% mol e DMF foram eleitos como as melhores condições de reação, com 43% de rendimento no caso do dímero usado no estudo de otimização (1a, N-metilado). O tempo reacional variou de entre 15 minutos e 11 dias, e rendimentos de 24 a 67%. Os 10 dímeros inéditos foram avaliados biologicamente nas linhagens de células cancerígenas K-569, HL-60 e A-549, e também em promastigotas e amastigotas de Leishmania infantum. Dentre os adutos enviados para avaliação de atividade antiproliferativa, apresentaram forte atividade 1h, um dímero Nbenzilado e diclorado (CI50 0,72 a 2,24 μM e IS 0,6 a 1,87), e 1f, um dímero N-metilado e diclorado (CI50 1,18 a 3,83 μM e IS 1,8 a 5,84), contra todas as cepas, sendo considerados promissores. Os dímeros deste trabalho foram mais ativos (CI50 1,18 a 7,94 μM) que os monômeros correspondentes existentes (CI50 4,2 a 16,08 μM) reportados na literatura, atestando a eficácia da dimerização para este caso. Nos testes in vitro em Leishmania infantum, 1h e 1f também se mostraram os mais ativos, com CI50 de 5,48 e 5,7 μM, respectivamente, na forma amastigota do parasito.Universidade Federal da ParaíbaBrasilQuímicaPrograma de Pós-Graduação em QuímicaUFPBLima Junior, Claudio Gabrielhttp://lattes.cnpq.br/5743384737397873Coelho, Maísa Cavalcanti2024-07-23T12:15:20Z2023-11-072024-07-23T12:15:20Z2023-07-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesishttps://repositorio.ufpb.br/jspui/handle/123456789/30921porAttribution-NoDerivs 3.0 Brazilhttp://creativecommons.org/licenses/by-nd/3.0/br/info:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFPBinstname:Universidade Federal da Paraíba (UFPB)instacron:UFPB2024-07-24T06:08:14Zoai:repositorio.ufpb.br:123456789/30921Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufpb.br/PUBhttp://tede.biblioteca.ufpb.br:8080/oai/requestdiretoria@ufpb.br|| diretoria@ufpb.bropendoar:2024-07-24T06:08:14Biblioteca Digital de Teses e Dissertações da UFPB - Universidade Federal da Paraíba (UFPB)false
dc.title.none.fl_str_mv Síntese de adutos de Morita-Baylis-Hillman simétricos derivados de isatina com atividade anticâncer e leishmanicida
title Síntese de adutos de Morita-Baylis-Hillman simétricos derivados de isatina com atividade anticâncer e leishmanicida
spellingShingle Síntese de adutos de Morita-Baylis-Hillman simétricos derivados de isatina com atividade anticâncer e leishmanicida
Coelho, Maísa Cavalcanti
Química
Adutos de Morita-Baylis-Hillman
Atividade antiproliferativa
Atividade antiparasitária
Aceptor de Michael
Simetria molecular
Morita-Baylis-Hillman adducts
Michael acceptor
Molecular symmetry
Antiproliferative activity
Antiparasitic activity
3-hidroxy-2-oxindol
CNPQ::CIENCIAS EXATAS E DA TERRA::QUIMICA
title_short Síntese de adutos de Morita-Baylis-Hillman simétricos derivados de isatina com atividade anticâncer e leishmanicida
title_full Síntese de adutos de Morita-Baylis-Hillman simétricos derivados de isatina com atividade anticâncer e leishmanicida
title_fullStr Síntese de adutos de Morita-Baylis-Hillman simétricos derivados de isatina com atividade anticâncer e leishmanicida
title_full_unstemmed Síntese de adutos de Morita-Baylis-Hillman simétricos derivados de isatina com atividade anticâncer e leishmanicida
title_sort Síntese de adutos de Morita-Baylis-Hillman simétricos derivados de isatina com atividade anticâncer e leishmanicida
author Coelho, Maísa Cavalcanti
author_facet Coelho, Maísa Cavalcanti
author_role author
dc.contributor.none.fl_str_mv Lima Junior, Claudio Gabriel
http://lattes.cnpq.br/5743384737397873
dc.contributor.author.fl_str_mv Coelho, Maísa Cavalcanti
dc.subject.por.fl_str_mv Química
Adutos de Morita-Baylis-Hillman
Atividade antiproliferativa
Atividade antiparasitária
Aceptor de Michael
Simetria molecular
Morita-Baylis-Hillman adducts
Michael acceptor
Molecular symmetry
Antiproliferative activity
Antiparasitic activity
3-hidroxy-2-oxindol
CNPQ::CIENCIAS EXATAS E DA TERRA::QUIMICA
topic Química
Adutos de Morita-Baylis-Hillman
Atividade antiproliferativa
Atividade antiparasitária
Aceptor de Michael
Simetria molecular
Morita-Baylis-Hillman adducts
Michael acceptor
Molecular symmetry
Antiproliferative activity
Antiparasitic activity
3-hidroxy-2-oxindol
CNPQ::CIENCIAS EXATAS E DA TERRA::QUIMICA
description Two important questions in human health, cancer and leishmaniasis have usual treatments that include injectable medicine with a lot of adverse effects, high cost and sometimes ineffective. In the context of need of new drugs development, the 3-hydroxy-2-oxindol scaffold is present in synthetic molecules with antiproliferative and leishmanicidal properties. In order to synthetize this nucleus, the Morita-Baylis-Hillman reaction (MBHR) can be used, and some adducts are already reported as anti-leishmania and antitumor. With the purpose of enhancing this activity, we used a molecular dimerization approach in the design of the novel molecules. The aim of this work was to obtain new dimmeric Morita-Baylis-Hillman adducts with potential antiproliferative and antiparasitic activity, containing the 3-hydroxy-2-oxindol nucleus formed by Morita-Baylis-Hillman reaction, using isatin as substrate. The synthetic route involved the synthesis of 10 isatin derivatives, the ethyleneglycol acrylate and the MBHR synthesis, forming the dimmeric Morita-Baylis-Hillman Adducts (MBHA). Variables as solvent, temperature, different catalysts and increasing proportions of DABCO (25 to 100%) were tested in the MBHA synthetic optimization. The novel dimmers were characterized by mass spectrometry, Fourier transform infrared (FTIR), 1H and 13C Nuclear Magnetic Resonance (NMR). Room temperature, DABCO 100 mol% and DMF were chosen as the best reaction conditions, with 43% yield in the case of the dimer used in the optimization study (1a, N-metilado). The reaction time varyied between 15 minutes to 11 days, and yields between 24 and 67%. 10 original dimmers were biologically evaluated in the cancer cell lines K-569, HL-60 e A-549 and also in promastigotes and amastigotes of Leishmania infantum. Among the adducts sent to antiproliferative evaluation, 1h, a Nbenzilated and dichlorated dimmer, presented strong activity against all the strains (IC50 0,72 to 2,24 μM and SI 0,6 to 1,87), as well 1f, a N-metilated and dichlorated dimmer (IC50 1,18 to 3,83 μM and SI 1,8 a 5,84), being both considered promising. The dimmers of this work (IC50 1,18 to 7,94 μM) were more active than the existing correspondent monomers (IC50 4,2 to 16,08 μM) reported in the literature, evidencing the efficacy of dimmerization approach in this case. The in vitro tests in Leishmania infantum showed 1h and 1f as the most active too, with IC50 of 5,48 and 5,7 μM, respectively, in the amastigote form of the parasite.
publishDate 2023
dc.date.none.fl_str_mv 2023-11-07
2023-07-28
2024-07-23T12:15:20Z
2024-07-23T12:15:20Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://repositorio.ufpb.br/jspui/handle/123456789/30921
url https://repositorio.ufpb.br/jspui/handle/123456789/30921
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv Attribution-NoDerivs 3.0 Brazil
http://creativecommons.org/licenses/by-nd/3.0/br/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NoDerivs 3.0 Brazil
http://creativecommons.org/licenses/by-nd/3.0/br/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade Federal da Paraíba
Brasil
Química
Programa de Pós-Graduação em Química
UFPB
publisher.none.fl_str_mv Universidade Federal da Paraíba
Brasil
Química
Programa de Pós-Graduação em Química
UFPB
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da UFPB
instname:Universidade Federal da Paraíba (UFPB)
instacron:UFPB
instname_str Universidade Federal da Paraíba (UFPB)
instacron_str UFPB
institution UFPB
reponame_str Biblioteca Digital de Teses e Dissertações da UFPB
collection Biblioteca Digital de Teses e Dissertações da UFPB
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações da UFPB - Universidade Federal da Paraíba (UFPB)
repository.mail.fl_str_mv diretoria@ufpb.br|| diretoria@ufpb.br
_version_ 1815449724679880704